Fine Chemicals Weekly News Round-up, April 12

Lonza this week disclosed that it has signed a contract to supply biotech firm Agennix (Heidelberg, Germany) with commercial quantities of Agennix's talactoferrin trial biopharma drug for treating lung cancer. The interesting fact here is that Lonza is the second European supplier. The primary supplier for the drug, which is in phase III trials, is DSM. Despite the low cost opportunities at hand to outsource production to China or India (or indeed other parts of Asia) Agennix is obviously keen to keep production close at hand in Europe. Lonza will be...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers